December 16, 2019
1 min read
Save
UK authority clears Roche acquisition of Spark
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The U.K. Competition and Markets Authority has cleared Roche’s pending acquisition of Spark Therapeutics, ruling the deal would not negatively affect competition, according to a press release.
An investigation by the CMA found that while Spark is developing a gene therapy treatment candidate for hemophilia A that is expected to compete with Roche’s Hemlibra (emicizumab-kxwh), there are other treatments in development from multiple suppliers.
Roche announced in February that it planned to fully acquire Spark for a price of $114.50 per share.
The deal, with a total equity value of more than $4 billion, still needs to be approved by the U.S. Federal Trade Commission.